Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $9.8700 (10.4%) ($9.1000 - $9.9000) on Tue. Feb. 4, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.16% (three month average) | RSI | 50 | Latest Price | $9.8700(10.4%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD advances 2% a day on average for past five trading days. | Weekly Trend | FOLD declines -4.9% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(60%) IWO(56%) XBI(55%) IWM(53%) IWC(51%) | Factors Impacting FOLD price | FOLD will decline at least -1.58% in a week (0% probabilities). VIXM(-33%) VXX(-19%) TLT(-14%) TIP(-1%) SHY(-1%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -1.58% (StdDev 3.16%) | Hourly BBV | 0 () | Intraday Trend | 6.8% | | | |
|
5 Day Moving Average | $9.19(7.4%) | 10 Day Moving Average | $9.17(7.63%) | 20 Day Moving Average | $9.47(4.22%) | To recent high | -8.2% | To recent low | 13.4% | Market Cap | $2.549b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |